These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 3519004

  • 1. Loss of luteinizing hormone bioactivity in patients with prostatic cancer treated with an LHRH agonist and a pure antiandrogen.
    St-Arnaud R, Lachance R, Kelly SJ, Belanger A, Dupont A, Labrie F.
    Clin Endocrinol (Oxf); 1986 Jan; 24(1):21-30. PubMed ID: 3519004
    [Abstract] [Full Text] [Related]

  • 2. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
    St Arnaud R, Lachance R, Dupont A, Labrie F.
    J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
    [Abstract] [Full Text] [Related]

  • 3. Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and flutamide in patients with cancer of the prostate.
    St-Arnaud R, Lachance R, Dupont A, Labrie F.
    Clin Invest Med; 1986 Nov; 9(4):215-21. PubMed ID: 2433088
    [Abstract] [Full Text] [Related]

  • 4. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
    Bélanger A, Labrie F, Dupont A, Brochu M, Cusan L.
    Clin Invest Med; 1988 Oct; 11(5):321-6. PubMed ID: 2972431
    [Abstract] [Full Text] [Related]

  • 5. Characteristics of flutamide action on prostatic and testicular functions in the rat.
    Marchetti B, Labrie F.
    J Steroid Biochem; 1988 Jun; 29(6):691-8. PubMed ID: 2838689
    [Abstract] [Full Text] [Related]

  • 6. The rise in testicular androgens during the first days of treatment with an LHRH agonist in the dog can be blocked by aminoglutethimide or ketoconazole.
    Lacoste D, St-Arnaud R, Caron S, Belanger A, Labrie F.
    J Steroid Biochem; 1988 Dec; 31(6):963-70. PubMed ID: 3059065
    [Abstract] [Full Text] [Related]

  • 7. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist.
    Labrie F, Dupont A, Belanger A, Lachance R.
    J Urol; 1987 Oct; 138(4):804-6. PubMed ID: 3309363
    [Abstract] [Full Text] [Related]

  • 8. Effect of 2-week combination therapy with the luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide and the antiandrogen flutamide on prostate structure and steroid levels in the dog.
    Lacoste D, Dubé D, Bélanger A, Labrie F.
    Mol Cell Endocrinol; 1989 Dec; 67(2-3):131-8. PubMed ID: 2693158
    [Abstract] [Full Text] [Related]

  • 9. A pure antiandrogen does not interfere with the LHRH agonist-induced blockade of testicular androgen secretion in the dog.
    Lacoste D, St-Arnaud R, Bélanger A, Labrie F.
    Mol Cell Endocrinol; 1988 Mar; 56(1-2):141-7. PubMed ID: 3286322
    [Abstract] [Full Text] [Related]

  • 10. Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model.
    Redding TW, Schally AV.
    Prostate; 1985 Mar; 6(3):219-32. PubMed ID: 3157927
    [Abstract] [Full Text] [Related]

  • 11. The luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6-Pro9-NEt]LHRH increased rather than lowered LH and alpha-subunit levels in a patient with an LH-secreting pituitary tumor.
    Roman SH, Goldstein M, Kourides IA, Comite F, Bardin CW, Krieger DT.
    J Clin Endocrinol Metab; 1984 Feb; 58(2):313-9. PubMed ID: 6198331
    [Abstract] [Full Text] [Related]

  • 12. Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations.
    Labrie F, Dupont A, Belanger A, Lachance R, Giguere M.
    Br Med J (Clin Res Ed); 1985 Aug 10; 291(6492):369-70. PubMed ID: 3926197
    [Abstract] [Full Text] [Related]

  • 13. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice.
    Labrie F, Dupont A, Cusan L, Giguere M, Bergeron N, Borsanyi JP, Lacourciere Y, Belanger A, Emond J, Monfette G.
    J Steroid Biochem; 1988 Aug 10; 30(1-6):107-17. PubMed ID: 3290578
    [Abstract] [Full Text] [Related]

  • 14. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
    Labrie F, Dupont A, Giguere M, Borsanyi JP, Belanger A, Lacourciere Y, Emond J, Monfette G.
    J Steroid Biochem; 1986 Nov 10; 25(5B):877-83. PubMed ID: 3100871
    [Abstract] [Full Text] [Related]

  • 15. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide.
    Moorjani S, Dupont A, Labrie F, Lupien PJ, Gagné C, Brun D, Giguère M, Bélanger A, Cusan L.
    J Clin Endocrinol Metab; 1988 Feb 10; 66(2):314-22. PubMed ID: 3276721
    [Abstract] [Full Text] [Related]

  • 16. Effect of 3-week treatment with [D-Trp6, des-Gly-NH10(2)]LHRH ethylamide, aminoglutethimide, ketoconazole or flutamide alone or in combination on testicular, serum, adrenal and prostatic steroid levels in the dog.
    Lacoste D, Caron S, Bélanger A, Labrie F.
    J Steroid Biochem; 1989 Aug 10; 33(2):233-42. PubMed ID: 2671505
    [Abstract] [Full Text] [Related]

  • 17. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients.
    Labrie F, Dupont A, Giguere M, Borsanyi JP, Lacourciere Y, Belanger A, Lachance R, Emond J, Monfette G.
    J Steroid Biochem; 1987 Aug 10; 27(1-3):525-32. PubMed ID: 2961937
    [Abstract] [Full Text] [Related]

  • 18. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Hall MC, Fritzsch RJ, Sagalowsky AI, Ahrens A, Petty B, Roehrborn CG.
    Urology; 1999 May 10; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
    [Abstract] [Full Text] [Related]

  • 19. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F, Dupont A, Giguère M, Borsanyi JP, Lacourciere Y, Bélanger A, Lachance R, Emond J, Monfette G.
    Prog Clin Biol Res; 1988 May 10; 260():41-62. PubMed ID: 3283766
    [Abstract] [Full Text] [Related]

  • 20. Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide.
    Bélanger A, Giasson M, Couture J, Dupont A, Cusan L, Labrie F.
    Prostate; 1988 May 10; 12(1):79-84. PubMed ID: 3279409
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.